---

Tuberculosis (TB) is an airborne global disease, which is typically caused by the Gram-positive bacterium Mycobacterium tuberculosis (Mtb). It remains to be one of the major infectious diseases globally.Despite 40 years of anti-TB chemotherapy, tuberculosis remains one of the leading infectious diseases worldwide. Among the main obstacles to the global control of the disease are the HIV epidemic that has dramatically increased risk for developing active TB, the increasing emergence of multi-drug resistant TB and the recalcitrance of persistent infections to treatment with conventional anti-TB drugs.The situation is exacerbated by the increasing emergence of extensively drug-resistant TB. A potential approach to overcome the resistance problem is to design novel and innovative agents. The development of new antibiotics can be achieved from derivatives of known antimicrobial agents or by identification of novel agents active against previously unexploited targets.Thus, keeping in view the need of novel antibacterial agents with improved antimicrobial profile, and as a part of our ongoing programme on design and discovery of novel pharmacotherapeutic and antimicrobial agents.

---

Noor Aldabagh and Mohammed Hassan are pharmacists; Ph.D in pharmaceutical chemistry. They are interesting with researches associated with design and chemical synthesis of novel compounds that targeting specific receptors and enzymes, as carbonic anhydrase, cyclo-oxygenase, and cancer cells.

---